AU2001280841A1 - Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B - Google Patents

Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B

Info

Publication number
AU2001280841A1
AU2001280841A1 AU2001280841A AU8084101A AU2001280841A1 AU 2001280841 A1 AU2001280841 A1 AU 2001280841A1 AU 2001280841 A AU2001280841 A AU 2001280841A AU 8084101 A AU8084101 A AU 8084101A AU 2001280841 A1 AU2001280841 A1 AU 2001280841A1
Authority
AU
Australia
Prior art keywords
vegf
seq
glycosylation site
nucleotide sequence
putative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280841A
Other languages
English (en)
Inventor
Kari Alitalo
Ulf Eriksson
Markku Jeltsch
Birgitta Olofsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Licentia Oy
Original Assignee
LUDWIG INST OF CANCER RES
Licentia Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUDWIG INST OF CANCER RES, Licentia Oy filed Critical LUDWIG INST OF CANCER RES
Publication of AU2001280841A1 publication Critical patent/AU2001280841A1/en
Assigned to LUDWIG INSTITUTE FOR CANCER RESEARCH, LICENTIA LTD. reassignment LUDWIG INSTITUTE FOR CANCER RESEARCH Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001280841A 2000-07-26 2001-07-26 Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B Abandoned AU2001280841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22082400P 2000-07-26 2000-07-26
US60220824 2000-07-26
PCT/US2001/023707 WO2002007514A2 (fr) 2000-07-26 2001-07-26 Vegf-b glycosylees et methode d'augmentation de la quantite de vegf-b solubles

Publications (1)

Publication Number Publication Date
AU2001280841A1 true AU2001280841A1 (en) 2002-02-05

Family

ID=22825121

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280841A Abandoned AU2001280841A1 (en) 2000-07-26 2001-07-26 Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B

Country Status (8)

Country Link
US (1) US20020068694A1 (fr)
EP (1) EP1303594A4 (fr)
JP (1) JP2004504042A (fr)
KR (1) KR20030074588A (fr)
CN (1) CN1461342A (fr)
AU (1) AU2001280841A1 (fr)
CA (1) CA2417508A1 (fr)
WO (1) WO2002007514A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
EP3118208A1 (fr) 2009-02-26 2017-01-18 Gen-Probe Incorporated Dosage pour la détection de l'acide nucléique parvovirus humain
JP7046828B2 (ja) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
SG11201808440YA (en) * 2016-04-15 2018-10-30 Regenxbio Inc Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
CN109932444B (zh) * 2019-03-19 2022-03-11 北京泰德制药股份有限公司 一种糖蛋白多种电荷异构体翻译后修饰的评价方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
CA2417508A1 (fr) 2002-01-31
EP1303594A2 (fr) 2003-04-23
JP2004504042A (ja) 2004-02-12
KR20030074588A (ko) 2003-09-19
CN1461342A (zh) 2003-12-10
EP1303594A4 (fr) 2004-07-14
US20020068694A1 (en) 2002-06-06
WO2002007514A2 (fr) 2002-01-31
WO2002007514A3 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
US6235713B1 (en) Vascular endothelial growth factor-D (VEGF-D) polypeptides
US6706687B1 (en) Platelet-derived growth factor D
US6541008B1 (en) Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof
CA2407970A1 (fr) Methode d'activation uniquement du recepteur-3 du facteur de croissance des cellules endotheliales vasculaires et ses utilisations
WO2000018212A9 (fr) Facteur de croissance c derive des plaquettes, adn le codant et ses utilisations
US20020164687A1 (en) Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20020164710A1 (en) Platelet-derived growth factor D, DNA coding therefor, and uses thereof
AU2001280841A1 (en) Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
US20070172423A1 (en) Composition and method for modulating vasculogenesis for angiogenesis
AU6502999A (en) Platelet-derived growth factor c, dna coding therefor, and uses thereof